A prospective study of the efficacy and the safety of the COVID-19 vaccines in NSCLC patients with UFT as postoperative adjuvant chemotherapy

A prospective study of the efficacy and the safety of the COVID-19 vaccines in NSCLC patients with UFT as postoperative adjuvant chemotherapy - A prospective study of the efficacy and the safety of the COVID-19 vaccines in NSCLC patients with UFT as postoperative adjuvant chemotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047380

Enrollment

Registered

2022-04-04

Start date

2021-07-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who plan to receive SARS-CoV-2 vaccines or within three months after the second dose of SARS-CoV-2 vaccines. 2. Patients who receive complete resection of NSCLC. 3. Patients who are over 20 years old. 4. Patients who submit written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients who have a history of COVID-19. 2. Patients who have any other infectious diseases under treatment. 3. Patients who receive immunosuppressive agents 4. Patients who receive treatment for other malignant diseases.

Design outcomes

Primary

Measure	Time frame
The IgG against the S1 subunit of spike protein	—

Countries

Japan

Contacts

Public ContactMegumi Nishikubo

Kobe University Graduate School of Medicine Division of Thoracic Surgery

megumin@med.kobe-u.ac.jp078-382-5750

Outcome results